CYTR CytRx Corporation

0.43
-0.01  -1%
Previous Close 0.43
Open 0.45
Price To book 3.57
Market Cap 71122686
Shares 165,825,800
Volume 1,030,758
Short Ratio 3.42
Av. Daily Volume 5,488,528

SEC filingsSee all SEC filings

  1. 8-K - Current report 171096231
  2. CT ORDER - Confidential treatment order 171087167
  3. 8-K - Current report 171083810
  4. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171081979
  5. 8-K - Current report 171060458

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b/2 poster at ASCO June 4, 2017. Abstract 11051.
Aldoxorubicin
Advanced sarcomas - cancer
Phase 3 PFS data released July 2016 showed no significant improvement in PFS. Second analysis released November 29, 2016 showed improvement in population with leiomyosarcoma and liposarcoma. Rolling NDA to be filed 4Q 2017.
Aldoxorubicin with doxorubicin
Soft tissue sarcomas refractory cancer
Phase 2 completed.
Aldoxorubicin
Cancer - AIDS-related Kaposi’s sarcoma
Phase 2 trial completed.
Aldoxorubicin
Cancer - unresectable glioblastoma
Phase 2b data due 2Q 2017 according to 1Q guidance. No mention in 2Q earnings report. MIA.
Aldoxorubicin
Relapsed/refractory small cell lung cancer

SEC Filings

  1. 8-K - Current report 171096231
  2. CT ORDER - Confidential treatment order 171087167
  3. 8-K - Current report 171083810
  4. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 171081979
  5. 8-K - Current report 171060458
  6. DEF 14A - Other definitive proxy statements 171058481
  7. 8-K - Current report 171049698
  8. 8-K - Current report 171043449
  9. PRE 14A - Other preliminary proxy statements 171041203
  10. 8-K/A [Amend] - Current report 171005676